Status:
COMPLETED
Apixaban in Patients With Left Ventricular Thrombus
Lead Sponsor:
Saud Al Babtain Cardiac Center
Conditions:
Left Ventricular Thrombus
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarc...
Eligibility Criteria
Inclusion
- All the following criteria must be fulfilled:
- Ages between 18 and 80 years,
- History of anterior wall MI, either acute (within a week) or recent (within a month)
- Evident left ventricular thrombus (LVT) by transthoracic echocardiography,
- Naïve to oral anticoagulants (OAC)
- stable to start OAC
Exclusion
- Other indications for OAC,
- Patients with contraindications for OAC,
- Right ventricular thrombus or atrial thrombus,
- History of confirmed stroke or other systemic embolization within the previous six months,
- High bleeding risk,
- Severe renal impairment,
- Patients with expected difficulties to follow the INR strictly.
Key Trial Info
Start Date :
February 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05208398
Start Date
February 18 2018
End Date
September 30 2021
Last Update
January 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saud AlBabtain Cardiac Center
Dammam, Saudi Arabia